p.99 抽出テキスト

cohort study and systematic review of literature. Lancet Diabetes Endocrinol 2021;9: 13–21. https://doi.org/10.1016/s2213-8587(20)30363-6 654. Martínez-Vizcaíno V, Sanabria-Martínez G, Fernández-Rodríguez R, Cavero-Redondo I, Pascual-Morena C, Álvarez-Bueno C, et al. Exercise during pregnancy for preventing gestational diabetes mellitus and hypertensive disorders: an umbrella review of randomised controlled trials and an updated meta-analysis. Bjog 2023;130:264–75. https:// doi.org/10.1111/1471-0528.17304 655. Mottola MF, Davenport MH, Ruchat SM, Davies GA, Poitras VJ, Gray CE, et al. 2019 Canadian guideline for physical activity throughout pregnancy. Br J Sports Med 2018;52: 1339–46. https://doi.org/10.1136/bjsports-2018-100056 656. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369: 1791–8. https://doi.org/10.1016/s0140-6736(07)60712-0 657. Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019;2019: CD004659. https://doi.org/10.1002/14651858.CD004659.pub3 658. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2018;10:CD001059. https://doi.org/10.1002/14651858.CD001059.pub5 659. Dwarkanath P, Muhihi A, Sudfeld CR, Wylie BJ, Wang M, Perumal N, et al. Two randomized trials of low-dose calcium supplementation in pregnancy. N Engl J Med 2024; 390:143–53. https://doi.org/10.1056/NEJMoa2307212 660. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018;10: CD002252. https://doi.org/10.1002/14651858.CD002252.pub4 661. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015;372:407–17. https:// doi.org/10.1056/NEJMoa1404595 662. Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 1976;2:753–6. https://doi.org/10.1016/s0140-6736(76)90597-3 663. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982;1:647–9. https://doi.org/10.1016/s0140-6736(82)92202-4 664. Bellos I, Pergialiotis V, Papapanagiotou A, Loutradis D, Daskalakis G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. Am J Obstet Gynecol 2020;223:525–37. https://doi.org/10.1016/j.ajog.2020.03.016 665. Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999;12:541–7. https://doi.org/10.1016/ s0895-7061(99)00031-x 666. Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol 2018;84:1906–16. https://doi.org/10.1111/bcp.13649 667. Bhat AD, Keasler PM, Kolluru L, Dombrowski MM, Palanisamy A, Singh PM, et al. Treatment of acute-onset hypertension in pregnancy: a network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration. Pregnancy Hypertens 2023;34:74–82. https://doi.org/10.1016/j.preghy.2023.10.005 668. Ehikioya E, Okobi OE, Beeko MAE, Abanga R, Abah NNI, Briggs L, et al. Comparing intravenous labetalol and intravenous hydralazine for managing severe gestational hypertension. Cureus 2023;15:e42332. https://doi.org/10.7759/cureus.42332 669. Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM, et al. Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:457–76. https://doi.org/10.1016/j.jacc.2018.10.075 670. Goel A, Maski MR, Bajracharya S, Wenger JB, Zhang D, Salahuddin S, et al. Epidemiology and mechanisms of de novo and persistent hypertension in the postpartum period. Circulation 2015;132:1726–33. https://doi.org/10.1161/circulationaha. 115.015721 671. Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, et al. Risk of postpregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ 2017;358:j3078. https://doi.org/10. 1136/bmj.j3078 672. Barrett PM, McCarthy FP, Evans M, Kublickas M, Perry IJ, Stenvinkel P, et al. Hypertensive disorders of pregnancy and the risk of chronic kidney disease: a Swedish registry-based cohort study. PLoS Med 2020;17:e1003255. https://doi.org/ 10.1371/journal.pmed.1003255 673. Giorgione V, Ridder A, Kalafat E, Khalil A, Thilaganathan B. Incidence of postpartum hypertension within 2 years of a pregnancy complicated by pre-eclampsia: a systematic review and meta-analysis. BJOG 2021;128:495–503. https://doi.org/10.1111/1471- 0528.16545 674. Benschop L, Duvekot JJ, Versmissen J, van Broekhoven V, Steegers EAP, Roeters van Lennep JE, et al. Blood pressure profile 1 year after severe preeclampsia. Hypertension 2018;71:491–8. https://doi.org/10.1161/hypertensionaha.117.10338 675. Kitt J, Fox R, Frost A, Shanyinde M, Tucker K, Bateman PA, et al. Long-term blood pressure control after hypertensive pregnancy following physician-optimized selfmanagement: the POP-HT randomized clinical trial. JAMA 2023;330:1991–9. https:// doi.org/10.1001/jama.2023.21523 676. van Oostwaard MF, Langenveld J, Schuit E, Papatsonis DNM, Brown MA, Byaruhanga RN, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol 2015;212:624.e1–17. https://doi.org/10.1016/j.ajog. 2015.01.009 677. Brown MA, Mackenzie C, Dunsmuir W, Roberts L, Ikin K, Matthews J, et al. Can we predict recurrence of pre-eclampsia or gestational hypertension? BJOG 2007;114: 984–93. https://doi.org/10.1111/j.1471-0528.2007.01376.x 678. Heimberger S, Perdigao JL, Mueller A, Shahul S, Naseem H, Minhas R, et al. Effect of blood pressure control in early pregnancy and clinical outcomes in African American women with chronic hypertension. Pregnancy Hypertens 2020;20:102–7. https://doi.org/10.1016/j.preghy.2020.03.008 679. Salazar MR, Espeche WG, Balbín E, Leiva Sisnieguez CE, Leiva Sisnieguez BC, Stavile RN, et al. Office blood pressure values and the necessity of out-of-office measurements in high-risk pregnancies. J Hypertens 2019;37:1838–44. https://doi.org/10. 1097/hjh.0000000000002140 680. Buawangpong N, Teekachunhatean S, Koonrungsesomboon N. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: a systematic review and meta-analysis. Pharmacol Res Perspect 2020;8:e00644. https://doi.org/10.1002/prp2.644 681. Weber-Schoendorfer C, Kayser A, Tissen-Diabaté T, Winterfeld U, Eleftheriou G, Te Winkel B, et al. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. J Hypertens 2020;38:133–41. https://doi.org/ 10.1097/hjh.0000000000002233 682. Chen X, Mao G, Leng SX. Frailty syndrome: an overview. Clin Interv Aging 2014;9: 433–41. https://doi.org/10.2147/cia.S45300 683. Rodriguez-Mañas L, Fried LP. Frailty in the clinical scenario. Lancet 2015;385:e7–9. https://doi.org/10.1016/s0140-6736(14)61595-6 684. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–156. https://doi.org/10.1093/gerona/56.3.m146 685. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the cardiovascular health study. JAMA 1998;279: 585–92. https://doi.org/10.1001/jama.279.8.585 686. Martens DS, Thijs L, Latosinska A, Trenson S, Siwy J, Zhang Z-Y, et al. Urinary peptidomic profiles to address age-related disabilities: a prospective population study. Lancet Healthy Longev 2021;2:e690–703. https://doi.org/10.1016/s2666-7568(21) 00226-9 687. Monahan KD. Effect of aging on baroreflex function in humans. Am J Physiol Regul Integr Comp Physiol 2007;293:R3–r12. https://doi.org/10.1152/ajpregu.00031.2007 688. Paleczny B, Niewiński P, Rydlewska A, Piepoli MF, Borodulin-Nadzieja L, Jankowska EA, et al. Age-related reflex responses from peripheral and central chemoreceptors in healthy men. Clin Auton Res 2014;24:285–96. https://doi.org/10.1007/s10286- 014-0263-9 689. Anker D, Santos-Eggimann B, Zwahlen M, Santschi V, Rodondi N, Wolfson C, et al. Blood pressure in relation to frailty in older adults: a population-based study. J Clin Hypertens (Greenwich) 2019;21:1895–904. https://doi.org/10.1111/jch.13722 690. Ravindrarajah R, Hazra NC, Hamada S, Charlton J, Jackson SHD, Dregan A, et al. Systolic blood pressure trajectory, frailty, and all-cause mortality >80 years of age: cohort study using electronic health records. Circulation 2017;135:2357–68. https://doi. org/10.1161/circulationaha.116.026687 691. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr 2008;8:24. https://doi.org/10.1186/1471- 2318-8-24 692. Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing 2016;45:353–60. https://doi.org/10.1093/ageing/afw039 693. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489–95. https:// doi.org/10.1503/cmaj.050051 694. Nguyen TN, Harris K, Woodward M, Chalmers J, Cooper M, Hamet P, et al. The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial. Diabetes Care 2021;44:1622–9. https://doi.org/10.2337/dc20-2664 695. Masoli JAH, Delgado J, Pilling L, Strain D, Melzer D. Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality. Age Ageing 2020;49: 807–13. https://doi.org/10.1093/ageing/afaa028 696. Aparicio LS, Thijs L, Boggia J, Jacobs L, Barochiner J, Odili AN, et al. Defining thresholds for home blood pressure monitoring in octogenarians. Hypertension 2015;66:865–73. https://doi.org/10.1161/hypertensionaha.115.05800 697. Gaffney B, Jacobsen AP, Pallippattu AW, Leahy N, McEvoy JW. The diastolic blood pressure J-curve in hypertension management: links and risk for cardiovascular disease. Integr Blood Press Control 2021;14:179–87. https://doi.org/10.2147/ibpc.S286957 698. Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026